Tumor angiogenesis in esophageal cancer

Abstract

Wang Wei, Hu Bing, He Yifu. Tumor angiogenesis in esophageal cancer[J]. Journal of International Oncology, 2014, 41(1): 31-34.

［1］ Hong L, Li S, Han Y, et al. Angiogenesisrelated molecular targets in esophageal cancer［J］. Expert Opin Investig Drugs, 2011, 20(5):637644. ［2］ Norguet E, Dahan L, Seitz JF. Targetting esophageal and gastric cancers with monoclonal antibodies［J］. Curr Top Med Chem, 2012, 12(15):16781682. ［3］ Barzi A, Lenz HJ. Angiogenesisrelated agents in esophageal cancer［J］. Expert Opin Biol Ther, 2012, 12(10):13351345. ［4］孙其恺, 吕阳, 王伟. periostin与肿瘤相关研究进展［J］. 中华外科杂志, 2013, 51(7):659661. ［5］ Jiang JT, Zhang LF, Zhou B, et al. Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis［J］. Asian Pac J Cancer Prev, 2012, 13(7):33793383. ［6］王确, 周儒白, 田李星, 等. 血管内皮生长因子与食管癌预后相关性的Meta分析［J］. 中国循证医学杂志, 2013, 13(5):553559. ［7］ Chen M, Cai E, Huang J, et al. Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and metaanalysis［J］. Cancer Epidemiol Biomarkers Prev, 2012, 21(7):11261134. ［8］ Lin C, Song L, Gong H, et al. Nkx28 downregulation promotes angiogenesis and activates NFκB in esophageal cancer［J］. Cancer Res, 2013, 73(12):36383648. ［9］ Sakurai T, Okumura H, Matsumoto M, et al. The expression of LC3 is related to tumor suppression through angiogenesis in esophageal cancer［J］. Med Oncol, 2013, 30(4):701. ［10］ Chen MF, Chen PT, Lu MS, et al. IL6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus［J］. Mol Cancer, 2013, 12:26. ［11］ Wang LD, Zhou FY, Li XM, et al. Genomewide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54［J］. Nat Genet, 2010, 42(9):759763. ［12］ Abnet CC, Freedman ND, Hu N, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma［J］. Nat Genet, 2010, 42(9):764767. ［13］ Wu C, Hu Z, He Z, et al. Genomewide association study identifies three new susceptibility loci for esophageal squamouscell carcinoma in Chinese populations［J］. Nat Genet, 2011, 43(7):679684. ［14］ Wong GS, Lee JS, Park YY, et al. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment［J］. Oncogenesis, 2013, 2:e59. ［15］ Shimada H, Takeda A, Nabeya Y, et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma［J］. Cancer, 2001, 92(3):663669. ［16］ Kozlowski M, Kowalczuk O, Milewski R, et al. Serum vascular endothelial growth factors C and D in patients with oesophageal cancer［J］. Eur J Cardiothorac Surg, 2010, 38(3):260267. ［17］季文豪, 凌志强, 毛伟敏. 食管癌治疗敏感基因单核苷酸多态性［J］. 国际肿瘤学杂志, 2011, 38(12):923926. ［18］ Bradbury PA, Zhai R, Ma C, et al. Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis［J］. Clin Cancer Res, 2009, 15(14):46804685. ［19］ Lurje G, Leers JM, Pohl A, et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus［J］. Ann Surg, 2010, 251(5):857864. ［20］ Lyros O, Mueller A, Heidel F, et al. Analysis of antiproliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multireceptor tyrosine kinase pathways［J］. Int J Cancer, 2010, 127(5):11971208. ［21］ Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer［J］. Expert Opin Emerg Drugs, 2009, 14(2):329339. ［22］ Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation［J］. Cancer Res, 1999, 59(14):33743378. ［23］ Arjaans M, Oude Munnink TH, Oosting SF, et al. Bevacizumabinduced normalization of blood vessels in tumors hampers antibody uptake［J］. Cancer Res, 2013, 73(11):33473355. ［24］ Liu J, Li Z, Cui J, et al. Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas［J］. Tumour Biol, 2012, 33(2):495505. ［25］ Goscinski MA, Nesland JM, Giercksky KE, et al. Primary tumor vascularity in esophagus cancer. CD34 and HIF1α expression correlate with tumor progression［J］. Histol Histopathol, 2013, 28(10):13611368.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[4]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[5]	Wang Kun, Zhou Zhongxin, Zang Qiwei.Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection[J]. Journal of International Oncology, 2024, 51(4): 198-203.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[8]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[11]	Wang Ting, Li Wenqian, Xie Youbang.Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells[J]. Journal of International Oncology, 2023, 50(8): 503-507.
[12]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer.Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition）[J]. Journal of International Oncology, 2023, 50(7): 385-397.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[15]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments